ClinicalTrials.gg
CompletedNCT06046443Updated Oct 30, 2026Results posted

A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity

A Phase 2 interventional study of Bivamelagon and Placebo in Hypothalamic Obesity, sponsored by Rhythm Pharmaceuticals, Inc.. Completed at 10 sites in 2 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Rhythm Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

Updated Oct 30, 2026Results postedStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Sexual Infantilism with a site in United States — 3 open to participants now, 6 under way, 2 of them phase 3. Sexual Infantilism · United States.

Enrollment
6th of 14
28 · median 27
Started
2024
with 2 others
Phase 2
7 of 14
1 open now
Registered
8th of 14
by date
Lead sponsor
7 of 14
Rhythm Pharmaceuticals, Inc.

Among the 14 studies in Sexual Infantilism with a site in United States, this one is the 6th largest by enrollment, is one of 3 that started in 2024, is one of 7 in phase 2, and was the 8th registered.

Sexual Infantilism

23 studies on the registry are indexed under Sexual Infantilism; 5 are open to participants now.

Browse Sexual Infantilism studies →

Open to participants now

3 of the 14 studies in Sexual Infantilism with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 3 Sexual Infantilism studies recruiting now, 2 set no upper age limit and 1 stops at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Sexual Infantilism with a site in United States, or all of them as a file.
02

Study summary

The goal of this study was to determine how well LB54640 (also known as bivamelagon) worked and how safe it was in participants with Hypothalamic Obesity (HO). The study evaluated the effect of bivamelagon on safety, weight reduction, hunger, and quality of life in participants 12 years of age and older with HO. Participants took an oral daily dose of either bivamelagon (low, middle, or high dose) or placebo through Week 14. Eligible participants who consented to continue in the study after Week 14 took an oral daily dose of bivamelagon through Week 52.

03

Conditions studied

  • Hypothalamic Obesity

Browse trials for

Keywords

  • melanocortin 4 receptor, MC4R
  • MC4R agonism
04

Who can participate

The criteria were revised on the registry on Oct 30, 2026. See what changed

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Documented evidence of acquired hypothalamic obesity (HO)
  • Age 12 years and older
  • Weight gain associated with the hypothalamic injury and a (BMI) of ≥30 kg/m\^2 for participants ≥18 years of age or BMI ≥95th percentile for age and sex for participants \<18 years of age
  • Male and female participants agreed to follow study requirements and use a highly effective form of contraception throughout the study and for 90 days after the study

Key Exclusion Criteria:

  • Weight loss >2% in the previous 3 months for participants ≥18 years of age or >2% reduction in BMI for participants \<18 years of age
  • History of major surgical procedure within 30 days
  • >10.9%
  • Fasting glucose level >270 mg/dL
  • Previous use of MC4R agonists
  • Diagnosis of Prader-Willi syndrome (PWS) or Rapid-onset obesity with hypoventilation, hypothalamic, autonomic dysregulation, neuroendocrine tumor syndrome (ROHHADNET)
  • Diagnosis of severe psychiatric disorders; any suicidal ideation, attempt or behavior
  • History or close family history of skin cancer or melanoma
  • pulmonary, cardiac, or oncologic disease considered severe enough to interfere with the study and/or confound the results

Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Bivamelagon Low dose (200 milligrams [mg])

    Participants were randomized to receive bivamelagon low dose (200 mg), middle dose (400 mg), or high dose (600 mg), or placebo by oral administration in a 1:1:1:1 ratio.

    Drug: Bivamelagon

  • Experimental
    Bivamelagon Middle dose (400 mg)

    Participants were randomized to receive bivamelagon low dose (200 mg), middle dose (400 mg), or high dose (600 mg), or placebo by oral administration in a 1:1:1:1 ratio.

    Drug: Bivamelagon

  • Experimental
    Bivamelagon High dose (600 mg)

    Participants were randomized to receive bivamelagon low dose (200 mg), middle dose (400 mg), or high dose (600 mg), or placebo by oral administration in a 1:1:1:1 ratio.

    Drug: Bivamelagon

  • Placebo comparator
    Placebo

    Participants were randomized to receive bivamelagon low dose (200 mg), middle dose (400 mg), or high dose (600 mg), or placebo by oral administration in a 1:1:1:1 ratio.

    Drug: Placebo

  • Experimental
    Open-label Bivamelagon

    Eligible participants who provided consent to continue into the open-label portion of the study received open-label bivamelagon.

    Drug: Bivamelagon

Interventions

  • Oral daily administration

    Also known as: LB54640

  • DrugPlacebo

    Placebo matched to LB54640

06

What researchers measure

Primary outcomes

  1. Treatment Phase: Mean Percentage Change From Baseline to Week 14 in Body Mass Index (BMI)

    BMI was calculated as weight (kilograms \[kg\])/height (squared meters \[m\^2\]). Least square mean (LSM) and standard error (SE) were calculated using analysis of covariance (ANCOVA) model with treatment group, randomization stratification factor (≥18 years old vs \<18 years old) as factors and baseline BMI as a covariate.

    Time frame: Baseline, Week 14

Secondary outcomes

  1. Treatment Phase: Mean Percentage Change From Baseline to Weeks 6 and 10 in BMI

    BMI was calculated as weight (kg)/height (m\^2). Percentage change from baseline was calculated as: (post-baseline result - baseline result) / baseline result\*100%.

    Time frame: Baseline, Week 6 and Week 10

  2. Treatment Phase: Mean Change From Baseline in BMI

    BMI was calculated as weight (kg)/height (m\^2).

    Time frame: Baseline, Week 6, Week 10, and Week 14

  3. Treatment Phase (Participants < 18 Years): Mean Change From Baseline in the Gender- and Age-specific BMI Z-Score

    The BMI Z-scores were measures of relative weight adjusted for child age and sex. Given a child's age, sex, BMI, and an appropriate reference standard, a BMI Z-score can be determined. The BMI Z-scores were calculated using the Lambda Mu and Sigma method following the 2007 World Health Organization (WHO) reference. A Z-score of 0 is equal to the mean of a reference population (i.e., healthy, age and sex-matched individuals). A decrease in BMI Z-score (\< 0) indicates a reduction in BMI from Baseline whereas an increase in BMI-Z score (\> 0) indicated an increase in BMI from Baseline.

    Time frame: Baseline, Week 6, Week 10, and Week 14

  4. Treatment Phase (Participants < 18 Years): Mean Change From Baseline in the Percentage of the Gender- and Age-specific 95th Percentile of BMI

    The BMI values were expressed as a percentage of the gender- and age-specific 95th percentile following the 2000 Centers for Disease Control (CDC) BMI-for-Age Growth Charts form.

    Time frame: Baseline, Week 6, Week 10, and Week 14

  5. Treatment Phase: Mean Change From Baseline in Body Weight

    Time frame: Baseline, Week 6, Week 10, and Week 14

  6. Treatment Phase: Mean Percentage Change From Baseline in Body Weight

    Percentage change from baseline was calculated as: (post-baseline result - baseline result) / baseline result\*100%.

    Time frame: Baseline, Week 6, Week 10, and Week 14

  7. Treatment Phase: Percentage of Participants Who Achieved at Least a ≥5% or ≥10% Reduction in Body Weight

    Time frame: Baseline to Week 14

  8. Treatment Phase: Percentage of Participants Who Achieved at Least a ≥5% or ≥10% Reduction in BMI

    BMI was calculated as weight (kg)/height (m\^2).

    Time frame: Baseline to Week 14

  9. Treatment Phase: Mean Change From Baseline in Waist Circumference

    The waist circumference was defined as the minimal abdominal circumference located midway between the lower rib margin and the iliac crest.

    Time frame: Baseline, Week 6, Week 10, and Week 14

  10. Treatment Phase: Mean Percentage Change From Baseline in Waist Circumference

    The waist circumference was defined as the minimal abdominal circumference located midway between the lower rib margin and the iliac crest. Percentage change from baseline was calculated as: (post-baseline result - baseline result) / baseline result\*100%.

    Time frame: Baseline, Week 6, Week 10, and Week 14

  11. Treatment Phase: Mean Change From Baseline in Waist-to-hip Circumference Ratio

    The waist circumference was defined as the minimal abdominal circumference located midway between the lower rib margin and the iliac crest. The hip circumference was defined as the widest circumference around the buttocks. The waist-to-hip ratio was calculated as waist circumference divided by hip circumference.

    Time frame: Baseline, Week 6, Week 10, and Week 14

  12. Treatment Phase: Mean Percentage Change From Baseline in Waist-to-hip Circumference Ratio

    The waist circumference was defined as the minimal abdominal circumference located midway between the lower rib margin and the iliac crest. The hip circumference was defined as the widest circumference around the buttocks. The waist-to-hip ratio was calculated as waist circumference divided by hip circumference. Percentage change from baseline was calculated as: (post-baseline result - baseline result) / baseline result\*100%.

    Time frame: Baseline, Week 6, Week 10, and Week 14

  13. Treatment Phase: Mean Change From Baseline in Body Composition

    Body composition included fat and lean body mass and was assessed by dual energy x-ray absorptiometry (DEXA).

    Time frame: Baseline, Week 14

  14. Treatment Phase: Mean Percentage Change From Baseline in Body Composition

    Body composition included fat and lean body mass and was assessed by DEXA. Percentage change from baseline was calculated as: (post-baseline result - baseline result) / baseline result\*100%.

    Time frame: Baseline, Week 14

  15. Treatment Phase: Mean Change From Baseline in the Weekly Average of the Daily Most Hunger Score

    Participants who were able to validly and reliably self-report were administered "Hunger Questions for Participants ≥12 Years of Age©." This questionnaire comprised 2 items (average and most hunger) that were designed to be evaluated separately (rather than as a composite score). Each item asked participants to rate their hunger on an 11-point numeric rating scale ranging from 0 to 10 (0 = not hungry at all and 10 = hungriest possible) with a recall period of 24 hours. Data reported are for mean change from baseline in the weekly average daily most hunger score.

    Time frame: Baseline, Week 14

  16. Treatment Phase: Mean Change From Baseline in the Weekly Average of the Symptoms of Hyperphagia Composite Score

    Participants who were able to self-report were administered the Symptoms of Hyperphagia: Patient© Version. The questionnaire consisted of 4 items related to the frequency of a participant's hyperphagia symptoms on a scale (never \[score 0\], 1 or 2 times \[score 1\], 3 or more times \[score 2\]) over the previous 24 hours. Caregivers of participants who could not self report were administered the Symptoms of Hyperphagia: Caregiver© Version which consisted of 5 items that included caregivers assessing the frequency of hyperphagia symptoms on a scale (never \[score 0\], 1 or 2 times \[score 1\], 3 or more times \[score 2\]) over the previous 24 hours for the person in their care. The composite score was derived by adding up all item scores and dividing by total number of items answered. The full range of the composite score was 0-2, with higher scores representing more hyperphagia. Data are reported for mean change from baseline in weekly average of symptoms of hyperphagia composite score.

    Time frame: Baseline, Week 14

  17. Open-label Extension Phase: Mean Change From Baseline in BMI

    BMI was calculated as weight (kg)/height (m\^2).

    Time frame: Baseline, Week 28 and Week 52

  18. Open-label Extension Phase: Mean Percentage Change From Baseline in BMI

    BMI was calculated as weight (kg)/height (m\^2). Percentage change from baseline was calculated as: (post-baseline result - baseline result) / baseline result\*100%.

    Time frame: Baseline, Week 28 and Week 52

  19. Open-label Extension Phase: Mean Change From Baseline in Body Weight

    Time frame: Baseline, Week 28 and Week 52

  20. Open-label Extension Phase: Mean Percentage Change From Baseline in Body Weight

    Percentage change from baseline was calculated as: (post-baseline result - baseline result) / baseline result\*100%.

    Time frame: Baseline, Week 28 and Week 52

  21. Open-label Extension Phase: Mean Change From Baseline in Waist Circumference

    The waist circumference was defined as the minimal abdominal circumference located midway between the lower rib margin and the iliac crest.

    Time frame: Baseline, Week 28 and Week 52

  22. Open-label Extension Phase: Mean Percentage Change From Baseline in Waist Circumference

    The waist circumference was defined as the minimal abdominal circumference located midway between the lower rib margin and the iliac crest. Percentage change from baseline was calculated as: (post-baseline result - baseline result) / baseline result\*100%.

    Time frame: Baseline, Week 28 and Week 52

  23. Open-label Extension Phase: Mean Change From Baseline in Waist-to-hip Circumference Ratio

    The waist circumference was defined as the minimal abdominal circumference located midway between the lower rib margin and the iliac crest. The hip circumference was defined as the widest circumference around the buttocks. The waist-to-hip ratio was calculated as waist circumference divided by hip circumference.

    Time frame: Baseline, Week 28 and Week 52

  24. Open-label Extension Phase: Mean Percentage Change From Baseline in Waist-to-hip Circumference Ratio

    The waist circumference was defined as the minimal abdominal circumference located midway between the lower rib margin and the iliac crest. The hip circumference was defined as the widest circumference around the buttocks. The waist-to-hip ratio was calculated as waist circumference divided by hip circumference. Percentage change from baseline was calculated as: (post-baseline result - baseline result) / baseline result\*100%.

    Time frame: Baseline, Week 28 and Week 52

  25. Open-label Extension Phase: Mean Change From Baseline in Body Composition

    Body composition included fat and lean body mass and was assessed by DEXA.

    Time frame: Baseline, Week 52

  26. Open-label Extension Phase: Mean Percentage Change From Baseline in Body Composition

    Body composition included fat and lean body mass and was assessed by DEXA. Percentage change from baseline was calculated as: (post-baseline result - baseline result) / baseline result\*100%.

    Time frame: Baseline, Week 52

  27. Treatment Phase: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) or Adverse Event of Special Interest (AESI)

    A TEAE was any undesirable and unintended medical event occurring to a participant in a clinical study and which did not necessarily have a causal relationship with the study drug, with onset or worsening after the start of study drug. AESIs were events of scientific and medical interest specific to further the understanding of the safety profile of the study drug. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

    Time frame: Day 1 to Week 14

  28. Open-label Extension Phase: Number of Participants Who Experienced a TEAE or AESI

    A TEAE was any undesirable and unintended medical event occurring to a participant in a clinical study and which does not necessarily have a causal relationship with the study drug, with onset or worsening after the start of study drug. AESIs were events of scientific and medical interest specific to the further understanding of the safety profile of the study drug. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

    Time frame: Week 14 to Week 56

  29. Treatment Phase: Number of Participants Who Experienced a Mild, Moderate, Severe, Life-threatening or Fatal TEAE

    TEAEs were evaluated by the investigator according to the definitions below using the following guidelines: * Mild - Asymptomatic or mild symptoms; clinical or diagnostic observations only; no intervention indicated; no disruption to daily activity. * Moderate - Discomfort sufficient to reduce or affect normal daily activity. * Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; inability to work or perform normal daily activity. * Life-threatening consequences; urgent intervention indicated. * Fatal outcome. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

    Time frame: Day 1 to Week 14

  30. Open-label Extension Phase: Number of Participants Who Experienced a Mild, Moderate, Severe, Life-threatening or Fatal TEAE

    TEAEs were evaluated by the investigator according to the definitions below using the following guidelines: * Mild - Asymptomatic or mild symptoms; clinical or diagnostic observations only; no intervention indicated; no disruption to daily activity. * Moderate - Discomfort sufficient to reduce or affect normal daily activity. * Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; inability to work or perform normal daily activity. * Life-threatening consequences; urgent intervention indicated. * Fatal outcome. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

    Time frame: Week 14 to Week 56

  31. Treatment Phase: Maximum Observed Concentration of Bivamelagon in Plasma (Cmax)

    Pharmacokinetic (PK) parameters were derived using noncompartmental methods. Cmax was obtained directly from the observed concentration versus time data. At Week 0, all participants received bivamelagon 200 mg QD. At Week 10, participants received their maximum assigned bivamelagon dose QD.

    Time frame: Week 0 and Week 10: Pre-dose and 1, 2, 4, 6, and 24 hours post-dose

  32. Treatment Phase: Time to Cmax (Tmax)

    PK parameters were derived using noncompartmental methods. At Week 0, all participants received bivamelagon 200 mg QD. At Week 10, participants received their maximum assigned bivamelagon dose QD.

    Time frame: Week 0 and Week 10: Pre-dose and 1, 2, 4, 6, and 24 hours post-dose

  33. Treatment Phase: Area Under the Concentration-time Curve From 0 to Last Quantifiable Concentration (AUC0-t)

    PK parameters were derived using noncompartmental methods.AUC0-t was calculated by the linear up/log down trapezoidal summation. At Week 0, all participants received bivamelagon 200 mg QD. At Week 10, participants received their maximum assigned bivamelagon dose QD.

    Time frame: Week 0 and Week 10: Pre-dose and 1, 2, 4, 6, and 24 hours post-dose

  34. Treatment Phase: Trough Plasma Concentration (Ctrough)

    PK parameters were derived using noncompartmental methods. At Week 0, all participants received bivamelagon 200 mg QD. At Week 10, participants received their maximum assigned bivamelagon dose QD.

    Time frame: Weeks 1, 2, 6, 10, and 14: Pre-dose

07

Results

Posted Oct 30, 2026

Participant flow

Double-blind Treatment Phase
Participant flow — Double-blind Treatment Phase
MilestoneBivamelagon 200 mgBivamelagon 400 mgBivamelagon 600 mgPlacebo
Started6787
Received study drug6787
Completed6687
Not completed0100
Withdrew: Adverse event0100
Open-label Extension Phase
Participant flow — Open-label Extension Phase
MilestoneBivamelagon 200 mgBivamelagon 400 mgBivamelagon 600 mgPlacebo
Started6677
Completed5676
Not completed1001
Withdrew: Adverse event0001
Withdrew: Other than specified1000

Outcome measures

PrimaryTreatment Phase: Mean Percentage Change From Baseline to Week 14 in Body Mass Index (BMI)

BMI was calculated as weight (kilograms \[kg\])/height (squared meters \[m\^2\]). Least square mean (LSM) and standard error (SE) were calculated using analysis of covariance (ANCOVA) model with treatment group, randomization stratification factor (≥18 years old vs \<18 years old) as factors and baseline BMI as a covariate.

Time frame:
Baseline, Week 14
Reported as:
Least squares mean · percentage change
Treatment Phase: Mean Percentage Change From Baseline to Week 14 in Body Mass Index (BMI)
percentage changeTreatment Phase: Bivamelagon 200 mgTreatment Phase: Bivamelagon 400 mgTreatment Phase: Bivamelagon 600 mgTreatment Phase: Placebo
Treatment Phase: Mean Percentage Change From Baseline to Week 14 in Body Mass Index (BMI)-2.62 ± 1.683-8.39 ± 1.738-9.98 ± 1.5572.52 ± 1.868
Statistical analysis
  • Treatment Phase: Bivamelagon 200 mg vs Treatment Phase: Placebo · ANCOVA · p = 0.0227 · Least square mean difference: -5.24 · 90% CI -9.02 to -1.46Bivamelagon - Placebo
  • Treatment Phase: Bivamelagon 400 mg vs Treatment Phase: Placebo · ANCOVA · p = 0.0000 · Least square mean difference: -11.00 · 90% CI -14.80 to -7.21Bivamelagon - Placebo
  • Treatment Phase: Bivamelagon 600 mg vs Treatment Phase: Placebo · ANCOVA · p = 0.0000 · Least square mean difference: -12.59 · 90% CI -16.32 to -8.87Bivamelagon - Placebo
SecondaryTreatment Phase: Mean Percentage Change From Baseline to Weeks 6 and 10 in BMI

BMI was calculated as weight (kg)/height (m\^2). Percentage change from baseline was calculated as: (post-baseline result - baseline result) / baseline result\*100%.

Time frame:
Baseline, Week 6 and Week 10
Reported as:
Mean · percentage change
Treatment Phase: Mean Percentage Change From Baseline to Weeks 6 and 10 in BMI
percentage changeTreatment Phase: Bivamelagon 200 mgTreatment Phase: Bivamelagon 400 mgTreatment Phase: Bivamelagon 600 mgTreatment Phase: Placebo
Week 6-1.06 ± 1.499-5.65 ± 1.600-5.80 ± 3.6510.02 ± 2.087
Week 10-6.47 ± 8.377-8.27 ± 2.304-8.07 ± 4.5030.64 ± 2.247
SecondaryTreatment Phase: Mean Change From Baseline in BMI

BMI was calculated as weight (kg)/height (m\^2).

Time frame:
Baseline, Week 6, Week 10, and Week 14
Reported as:
Mean · kilograms per square meter (kg/m^2)
Treatment Phase: Mean Change From Baseline in BMI
kilograms per square meter (kg/m^2)Treatment Phase: Bivamelagon 200 mgTreatment Phase: Bivamelagon 400 mgTreatment Phase: Bivamelagon 600 mgTreatment Phase: Placebo
Week 6-0.45 ± 0.610-2.13 ± 0.839-2.47 ± 1.6920.05 ± 0.766
Week 10-2.25 ± 2.670-3.08 ± 1.045-3.36 ± 2.0000.31 ± 0.945
Week 14-1.10 ± 1.285-3.31 ± 1.508-4.12 ± 2.5420.88 ± 1.154
SecondaryTreatment Phase (Participants < 18 Years): Mean Change From Baseline in the Gender- and Age-specific BMI Z-Score

The BMI Z-scores were measures of relative weight adjusted for child age and sex. Given a child's age, sex, BMI, and an appropriate reference standard, a BMI Z-score can be determined. The BMI Z-scores were calculated using the Lambda Mu and Sigma method following the 2007 World Health Organization (WHO) reference. A Z-score of 0 is equal to the mean of a reference population (i.e., healthy, age and sex-matched individuals). A decrease in BMI Z-score (\< 0) indicates a reduction in BMI from Baseline whereas an increase in BMI-Z score (\> 0) indicated an increase in BMI from Baseline.

Time frame:
Baseline, Week 6, Week 10, and Week 14
Reported as:
Mean · BMI z-score
Treatment Phase (Participants < 18 Years): Mean Change From Baseline in the Gender- and Age-specific BMI Z-Score
BMI z-scoreTreatment Phase: Bivamelagon 200 mgTreatment Phase: Bivamelagon 400 mgTreatment Phase: Bivamelagon 600 mgTreatment Phase: Placebo
Week 6-0.02 ± 0.055-0.30 ± 0.030-0.15 ± 0.039-0.04 ± 0.105
Week 10-0.53 ± 0.774-0.44 ± 0.100-0.23 ± 0.121-0.04 ± 0.046
Week 14-0.04 ± 0.104-0.49 ± 0.235-0.33 ± 0.2700.06 ± 0.035
SecondaryTreatment Phase (Participants < 18 Years): Mean Change From Baseline in the Percentage of the Gender- and Age-specific 95th Percentile of BMI

The BMI values were expressed as a percentage of the gender- and age-specific 95th percentile following the 2000 Centers for Disease Control (CDC) BMI-for-Age Growth Charts form.

Time frame:
Baseline, Week 6, Week 10, and Week 14
Reported as:
Mean · percentage of the 95th percentile of BMI
Treatment Phase (Participants < 18 Years): Mean Change From Baseline in the Percentage of the Gender- and Age-specific 95th Percentile of BMI
percentage of the 95th percentile of BMITreatment Phase: Bivamelagon 200 mgTreatment Phase: Bivamelagon 400 mgTreatment Phase: Bivamelagon 600 mgTreatment Phase: Placebo
Week 6-0.38 ± 1.401-7.11 ± 2.249-3.96 ± 1.386-1.37 ± 2.848
Week 10-11.56 ± 16.321-10.000 ± 3.918-5.79 ± 3.269-1.19 ± 1.122
Week 14-1.27 ± 2.978-10.71 ± 5.741-8.43 ± 7.4081.16 ± 0.180
SecondaryTreatment Phase: Mean Change From Baseline in Body Weight
Time frame:
Baseline, Week 6, Week 10, and Week 14
Reported as:
Mean · kilograms
Treatment Phase: Mean Change From Baseline in Body Weight
kilogramsTreatment Phase: Bivamelagon 200 mgTreatment Phase: Bivamelagon 400 mgTreatment Phase: Bivamelagon 600 mgTreatment Phase: Placebo
Week 6-1.70 ± 1.816-5.79 ± 2.556-6.58 ± 4.0200.37 ± 1.991
Week 10-2.88 ± 2.947-8.32 ± 2.959-8.77 ± 5.5671.64 ± 2.772
Week 14-2.83 ± 4.864-8.97 ± 4.255-10.49 ± 7.3322.97 ± 3.681
SecondaryTreatment Phase: Mean Percentage Change From Baseline in Body Weight

Percentage change from baseline was calculated as: (post-baseline result - baseline result) / baseline result\*100%.

Time frame:
Baseline, Week 6, Week 10, and Week 14
Reported as:
Mean · percentage change
Treatment Phase: Mean Percentage Change From Baseline in Body Weight
percentage changeTreatment Phase: Bivamelagon 200 mgTreatment Phase: Bivamelagon 400 mgTreatment Phase: Bivamelagon 600 mgTreatment Phase: Placebo
Week 6-1.25 ± 1.295-5.61 ± 1.665-5.98 ± 3.5500.41 ± 1.941
Week 10-2.32 ± 2.403-8.16 ± 2.104-8.03 ± 4.6551.54 ± 2.122
Week 14-1.75 ± 3.808-8.60 ± 3.161-9.64 ± 6.1122.73 ± 2.679
SecondaryTreatment Phase: Percentage of Participants Who Achieved at Least a ≥5% or ≥10% Reduction in Body Weight
Time frame:
Baseline to Week 14
Reported as:
Number · percentage of participants
Treatment Phase: Percentage of Participants Who Achieved at Least a ≥5% or ≥10% Reduction in Body Weight
percentage of participantsTreatment Phase: Bivamelagon 200 mgTreatment Phase: Bivamelagon 400 mgTreatment Phase: Bivamelagon 600 mgTreatment Phase: Placebo
At Least a ≥5% Reduction in Body Weight16.7 (0.9 to 58.2)85.7 (56.7 to 100.0)75.0 (40.0 to 95.4)0 (0.0 to 34.8)
At Least a ≥10% Reduction in Body Weight0 (NA to NA)14.3 (0.0 to 44.3)37.5 (11.1 to 71.1)0 (0.00 to 34.8)
SecondaryTreatment Phase: Percentage of Participants Who Achieved at Least a ≥5% or ≥10% Reduction in BMI

BMI was calculated as weight (kg)/height (m\^2).

Time frame:
Baseline to Week 14
Reported as:
Number · percentage of participants
Treatment Phase: Percentage of Participants Who Achieved at Least a ≥5% or ≥10% Reduction in BMI
percentage of participantsTreatment Phase: Bivamelagon 200 mgTreatment Phase: Bivamelagon 400 mgTreatment Phase: Bivamelagon 600 mgTreatment Phase: Placebo
At Least a ≥5% Reduction in BMI16.7 (0.9 to 58.2)85.7 (56.7 to 100.0)75.0 (40.0 to 95.4)0 (0.0 to 34.8)
At Least a ≥10% Reduction in BMI0 (NA to NA)14.3 (0.0 to 44.3)37.5 (11.1 to 71.1)0 (0.00 to 34.8)
SecondaryTreatment Phase: Mean Change From Baseline in Waist Circumference

The waist circumference was defined as the minimal abdominal circumference located midway between the lower rib margin and the iliac crest.

Time frame:
Baseline, Week 6, Week 10, and Week 14
Reported as:
Mean · centimeters
Treatment Phase: Mean Change From Baseline in Waist Circumference
centimetersTreatment Phase: Bivamelagon 200 mgTreatment Phase: Bivamelagon 400 mgTreatment Phase: Bivamelagon 600 mgTreatment Phase: Placebo
Week 6-1.42 ± 1.469-4.90 ± 1.298-7.20 ± 5.738-3.97 ± 4.875
Week 10-5.02 ± 5.226-4.50 ± 2.956-5.60 ± 4.840-1.94 ± 3.208
Week 14-2.73 ± 3.822-7.75 ± 1.787-6.17 ± 6.2751.49 ± 2.060
SecondaryTreatment Phase: Mean Percentage Change From Baseline in Waist Circumference

The waist circumference was defined as the minimal abdominal circumference located midway between the lower rib margin and the iliac crest. Percentage change from baseline was calculated as: (post-baseline result - baseline result) / baseline result\*100%.

Time frame:
Baseline, Week 6, Week 10, and Week 14
Reported as:
Mean · percentage change
Treatment Phase: Mean Percentage Change From Baseline in Waist Circumference
percentage changeTreatment Phase: Bivamelagon 200 mgTreatment Phase: Bivamelagon 400 mgTreatment Phase: Bivamelagon 600 mgTreatment Phase: Placebo
Week 6-1.22 ± 1.236-4.73 ± 1.534-6.00 ± 4.708-4.18 ± 5.206
Week 10-4.20 ± 4.307-4.40 ± 2.844-4.79 ± 3.841-1.94 ± 3.453
Week 14-2.17 ± 2.904-7.39 ± 1.842-5.17 ± 5.2911.19 ± 1.937
SecondaryTreatment Phase: Mean Change From Baseline in Waist-to-hip Circumference Ratio

The waist circumference was defined as the minimal abdominal circumference located midway between the lower rib margin and the iliac crest. The hip circumference was defined as the widest circumference around the buttocks. The waist-to-hip ratio was calculated as waist circumference divided by hip circumference.

Time frame:
Baseline, Week 6, Week 10, and Week 14
Reported as:
Mean · ratio
Treatment Phase: Mean Change From Baseline in Waist-to-hip Circumference Ratio
ratioTreatment Phase: Bivamelagon 200 mgTreatment Phase: Bivamelagon 400 mgTreatment Phase: Bivamelagon 600 mgTreatment Phase: Placebo
Week 6-0.01 ± 0.0310.00 ± 0.028-0.03 ± 0.035-0.05 ± 0.053
Week 10-0.02 ± 0.0270.02 ± 0.0490.01 ± 0.056-0.04 ± 0.041
Week 14-0.02 ± 0.035-0.01 ± 0.031-0.02 ± 0.0280.02 ± 0.029
SecondaryTreatment Phase: Mean Percentage Change From Baseline in Waist-to-hip Circumference Ratio

The waist circumference was defined as the minimal abdominal circumference located midway between the lower rib margin and the iliac crest. The hip circumference was defined as the widest circumference around the buttocks. The waist-to-hip ratio was calculated as waist circumference divided by hip circumference. Percentage change from baseline was calculated as: (post-baseline result - baseline result) / baseline result\*100%.

Time frame:
Baseline, Week 6, Week 10, and Week 14
Reported as:
Mean · percentage change
Treatment Phase: Mean Percentage Change From Baseline in Waist-to-hip Circumference Ratio
percentage changeTreatment Phase: Bivamelagon 200 mgTreatment Phase: Bivamelagon 400 mgTreatment Phase: Bivamelagon 600 mgTreatment Phase: Placebo
Week 6-0.53 ± 3.0750.33 ± 3.158-3.41 ± 3.449-4.90 ± 5.371
Week 10-1.71 ± 2.7232.51 ± 5.5991.24 ± 5.688-3.77 ± 4.004
Week 14-1.79 ± 3.506-1.41 ± 3.416-2.31 ± 2.7912.12 ± 3.078
SecondaryTreatment Phase: Mean Change From Baseline in Body Composition

Body composition included fat and lean body mass and was assessed by dual energy x-ray absorptiometry (DEXA).

Time frame:
Baseline, Week 14
Reported as:
Mean · kilograms
Treatment Phase: Mean Change From Baseline in Body Composition
kilogramsTreatment Phase: Bivamelagon 200 mgTreatment Phase: Bivamelagon 400 mgTreatment Phase: Bivamelagon 600 mgTreatment Phase: Placebo
Body Fat Mass3.07 ± 12.531-5.30 ± 3.026-5.65 ± 4.9901.11 ± 2.466
Body Lean Mass-3.09 ± 3.092-2.58 ± 2.192-3.35 ± 3.1510.95 ± 1.450
SecondaryTreatment Phase: Mean Percentage Change From Baseline in Body Composition

Body composition included fat and lean body mass and was assessed by DEXA. Percentage change from baseline was calculated as: (post-baseline result - baseline result) / baseline result\*100%.

Time frame:
Baseline, Week 14
Reported as:
Mean · percentage change
Treatment Phase: Mean Percentage Change From Baseline in Body Composition
percentage changeTreatment Phase: Bivamelagon 200 mgTreatment Phase: Bivamelagon 400 mgTreatment Phase: Bivamelagon 600 mgTreatment Phase: Placebo
Body Fat Mass12.92 ± 40.349-11.43 ± 3.639-11.79 ± 8.1342.72 ± 5.919
Body Lean Mass-4.76 ± 5.699-4.51 ± 2.864-6.20 ± 5.8901.68 ± 2.714
SecondaryTreatment Phase: Mean Change From Baseline in the Weekly Average of the Daily Most Hunger Score

Participants who were able to validly and reliably self-report were administered "Hunger Questions for Participants ≥12 Years of Age©." This questionnaire comprised 2 items (average and most hunger) that were designed to be evaluated separately (rather than as a composite score). Each item asked participants to rate their hunger on an 11-point numeric rating scale ranging from 0 to 10 (0 = not hungry at all and 10 = hungriest possible) with a recall period of 24 hours. Data reported are for mean change from baseline in the weekly average daily most hunger score.

Time frame:
Baseline, Week 14
Reported as:
Mean · score on a scale
Treatment Phase: Mean Change From Baseline in the Weekly Average of the Daily Most Hunger Score
score on a scaleTreatment Phase: Bivamelagon 200 mgTreatment Phase: Bivamelagon 400 mgTreatment Phase: Bivamelagon 600 mgTreatment Phase: Placebo
Treatment Phase: Mean Change From Baseline in the Weekly Average of the Daily Most Hunger Score-2.07 ± 1.169-2.77 ± 1.486-2.84 ± 2.299-0.77 ± 1.674
SecondaryTreatment Phase: Mean Change From Baseline in the Weekly Average of the Symptoms of Hyperphagia Composite Score

Participants who were able to self-report were administered the Symptoms of Hyperphagia: Patient© Version. The questionnaire consisted of 4 items related to the frequency of a participant's hyperphagia symptoms on a scale (never \[score 0\], 1 or 2 times \[score 1\], 3 or more times \[score 2\]) over the previous 24 hours. Caregivers of participants who could not self report were administered the Symptoms of Hyperphagia: Caregiver© Version which consisted of 5 items that included caregivers assessing the frequency of hyperphagia symptoms on a scale (never \[score 0\], 1 or 2 times \[score 1\], 3 or more times \[score 2\]) over the previous 24 hours for the person in their care. The composite score was derived by adding up all item scores and dividing by total number of items answered. The full range of the composite score was 0-2, with higher scores representing more hyperphagia. Data are reported for mean change from baseline in weekly average of symptoms of hyperphagia composite score.

Time frame:
Baseline, Week 14
Reported as:
Mean · score on a scale
Treatment Phase: Mean Change From Baseline in the Weekly Average of the Symptoms of Hyperphagia Composite Score
score on a scaleTreatment Phase: Bivamelagon 200 mgTreatment Phase: Bivamelagon 400 mgTreatment Phase: Bivamelagon 600 mgTreatment Phase: Placebo
Treatment Phase: Mean Change From Baseline in the Weekly Average of the Symptoms of Hyperphagia Composite Score-0.49 ± 0.409-0.25 ± 0.273-0.21 ± 0.239-0.23 ± 0.255
SecondaryOpen-label Extension Phase: Mean Change From Baseline in BMI

BMI was calculated as weight (kg)/height (m\^2).

Time frame:
Baseline, Week 28 and Week 52
Reported as:
Mean · kg/m^2
Open-label Extension Phase: Mean Change From Baseline in BMI
kg/m^2Open-label Extension Phase: Bivamelagon 200 mg to 600 mgOpen-label Extension Phase: Bivamelagon 400 mg to 600 mgOpen-label Extension Phase: Bivamelagon 600 mg to 600 mgOpen-label Extension Phase: Placebo to Bivamelagon 600 mg
Week 28-3.14 ± 1.958-4.14 ± 2.438-5.64 ± 3.743-1.90 ± 1.745
Week 52-2.56 ± 4.373-3.90 ± 3.487-6.98 ± 5.756-3.15 ± 2.159
SecondaryOpen-label Extension Phase: Mean Percentage Change From Baseline in BMI

BMI was calculated as weight (kg)/height (m\^2). Percentage change from baseline was calculated as: (post-baseline result - baseline result) / baseline result\*100%.

Time frame:
Baseline, Week 28 and Week 52
Reported as:
Mean · percentage change
Open-label Extension Phase: Mean Percentage Change From Baseline in BMI
percentage changeOpen-label Extension Phase: Bivamelagon 200 mg to 600 mgOpen-label Extension Phase: Bivamelagon 400 mg to 600 mgOpen-label Extension Phase: Bivamelagon 600 mg to 600 mgOpen-label Extension Phase: Placebo to Bivamelagon 600 mg
Week 28-8.51 ± 5.658-11.73 ± 7.265-13.60 ± 8.893-5.53 ± 5.000
Week 52-6.66 ± 11.880-10.77 ± 10.386-16.58 ± 13.174-8.66 ± 6.095
SecondaryOpen-label Extension Phase: Mean Change From Baseline in Body Weight
Time frame:
Baseline, Week 28 and Week 52
Reported as:
Mean · kilograms
Open-label Extension Phase: Mean Change From Baseline in Body Weight
kilogramsOpen-label Extension Phase: Bivamelagon 200 mg to 600 mgOpen-label Extension Phase: Bivamelagon 400 mg to 600 mgOpen-label Extension Phase: Bivamelagon 600 mg to 600 mgOpen-label Extension Phase: Placebo to Bivamelagon 600 mg
Week 28-5.27 ± 8.273-11.33 ± 7.316-13.70 ± 10.469-5.04 ± 7.205
Week 52-3.50 ± 14.460-11.18 ± 9.845-17.31 ± 15.747-8.66 ± 9.502
SecondaryOpen-label Extension Phase: Mean Percentage Change From Baseline in Body Weight

Percentage change from baseline was calculated as: (post-baseline result - baseline result) / baseline result\*100%.

Time frame:
Baseline, Week 28 and Week 52
Reported as:
Mean · percentage change
Open-label Extension Phase: Mean Percentage Change From Baseline in Body Weight
percentage changeOpen-label Extension Phase: Bivamelagon 200 mg to 600 mgOpen-label Extension Phase: Bivamelagon 400 mg to 600 mgOpen-label Extension Phase: Bivamelagon 600 mg to 600 mgOpen-label Extension Phase: Placebo to Bivamelagon 600 mg
Week 28-3.61 ± 6.703-11.22 ± 7.608-13.11 ± 8.835-4.72 ± 5.272
Week 52-0.77 ± 12.846-10.56 ± 10.264-16.06 ± 12.899-7.08 ± 7.020
SecondaryOpen-label Extension Phase: Mean Change From Baseline in Waist Circumference

The waist circumference was defined as the minimal abdominal circumference located midway between the lower rib margin and the iliac crest.

Time frame:
Baseline, Week 28 and Week 52
Reported as:
Mean · centimeters
Open-label Extension Phase: Mean Change From Baseline in Waist Circumference
centimetersOpen-label Extension Phase: Bivamelagon 200 mg to 600 mgOpen-label Extension Phase: Bivamelagon 400 mg to 600 mgOpen-label Extension Phase: Bivamelagon 600 mg to 600 mgOpen-label Extension Phase: Placebo to Bivamelagon 600 mg
Week 28-3.33 ± 5.702-8.45 ± 5.218-10.30 ± 7.208-5.06 ± 4.970
Week 52-3.18 ± 9.899-6.73 ± 6.230-14.47 ± 10.224-4.30 ± 12.325
SecondaryOpen-label Extension Phase: Mean Percentage Change From Baseline in Waist Circumference

The waist circumference was defined as the minimal abdominal circumference located midway between the lower rib margin and the iliac crest. Percentage change from baseline was calculated as: (post-baseline result - baseline result) / baseline result\*100%.

Time frame:
Baseline, Week 28 and Week 52
Reported as:
Mean · percentage change
Open-label Extension Phase: Mean Percentage Change From Baseline in Waist Circumference
percentage changeOpen-label Extension Phase: Bivamelagon 200 mg to 600 mgOpen-label Extension Phase: Bivamelagon 400 mg to 600 mgOpen-label Extension Phase: Bivamelagon 600 mg to 600 mgOpen-label Extension Phase: Placebo to Bivamelagon 600 mg
Week 28-2.57 ± 4.466-8.19 ± 5.945-8.92 ± 6.441-5.09 ± 5.177
Week 52-2.40 ± 8.141-6.31 ± 5.773-12.22 ± 8.797-3.30 ± 12.237
SecondaryOpen-label Extension Phase: Mean Change From Baseline in Waist-to-hip Circumference Ratio

The waist circumference was defined as the minimal abdominal circumference located midway between the lower rib margin and the iliac crest. The hip circumference was defined as the widest circumference around the buttocks. The waist-to-hip ratio was calculated as waist circumference divided by hip circumference.

Time frame:
Baseline, Week 28 and Week 52
Reported as:
Mean · ratio
Open-label Extension Phase: Mean Change From Baseline in Waist-to-hip Circumference Ratio
ratioOpen-label Extension Phase: Bivamelagon 200 mg to 600 mgOpen-label Extension Phase: Bivamelagon 400 mg to 600 mgOpen-label Extension Phase: Bivamelagon 600 mg to 600 mgOpen-label Extension Phase: Placebo to Bivamelagon 600 mg
Week 28-0.01 ± 0.0390.02 ± 0.066-0.00 ± 0.074-0.02 ± 0.044
Week 52-0.03 ± 0.036-0.00 ± 0.049-0.04 ± 0.036-0.03 ± 0.051
SecondaryOpen-label Extension Phase: Mean Percentage Change From Baseline in Waist-to-hip Circumference Ratio

The waist circumference was defined as the minimal abdominal circumference located midway between the lower rib margin and the iliac crest. The hip circumference was defined as the widest circumference around the buttocks. The waist-to-hip ratio was calculated as waist circumference divided by hip circumference. Percentage change from baseline was calculated as: (post-baseline result - baseline result) / baseline result\*100%.

Time frame:
Baseline, Week 28 and Week 52
Reported as:
Mean · percentage change
Open-label Extension Phase: Mean Percentage Change From Baseline in Waist-to-hip Circumference Ratio
percentage changeOpen-label Extension Phase: Bivamelagon 200 mg to 600 mgOpen-label Extension Phase: Bivamelagon 400 mg to 600 mgOpen-label Extension Phase: Bivamelagon 600 mg to 600 mgOpen-label Extension Phase: Placebo to Bivamelagon 600 mg
Week 28-1.37 ± 3.9362.15 ± 7.6360.19 ± 8.635-2.42 ± 4.774
Week 52-3.39 ± 3.622-0.44 ± 5.403-4.07 ± 3.362-3.05 ± 5.289
SecondaryOpen-label Extension Phase: Mean Change From Baseline in Body Composition

Body composition included fat and lean body mass and was assessed by DEXA.

Time frame:
Baseline, Week 52
Reported as:
Mean · kilograms
Open-label Extension Phase: Mean Change From Baseline in Body Composition
kilogramsOpen-label Extension Phase: Bivamelagon 200 mg to 600 mgOpen-label Extension Phase: Bivamelagon 400 mg to 600 mgOpen-label Extension Phase: Bivamelagon 600 mg to 600 mgOpen-label Extension Phase: Placebo to Bivamelagon 600 mg
Body Fat Mass-5.55 ± 7.853-9.47 ± 6.030-13.26 ± 9.929-4.70 ± 4.971
Body Lean Mass-2.32 ± 5.007-5.54 ± 3.242-4.87 ± 7.032-2.39 ± 5.731
SecondaryOpen-label Extension Phase: Mean Percentage Change From Baseline in Body Composition

Body composition included fat and lean body mass and was assessed by DEXA. Percentage change from baseline was calculated as: (post-baseline result - baseline result) / baseline result\*100%.

Time frame:
Baseline, Week 52
Reported as:
Mean · percentage change
Open-label Extension Phase: Mean Percentage Change From Baseline in Body Composition
percentage changeOpen-label Extension Phase: Bivamelagon 200 mg to 600 mgOpen-label Extension Phase: Bivamelagon 400 mg to 600 mgOpen-label Extension Phase: Bivamelagon 600 mg to 600 mgOpen-label Extension Phase: Placebo to Bivamelagon 600 mg
Body Fat Mass-9.14 ± 14.707-20.12 ± 8.170-28.74 ± 17.588-10.40 ± 9.936
Body Lean Mass-1.87 ± 6.464-10.83 ± 7.516-8.40 ± 12.617-3.55 ± 8.115
SecondaryTreatment Phase: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) or Adverse Event of Special Interest (AESI)

A TEAE was any undesirable and unintended medical event occurring to a participant in a clinical study and which did not necessarily have a causal relationship with the study drug, with onset or worsening after the start of study drug. AESIs were events of scientific and medical interest specific to further the understanding of the safety profile of the study drug. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

Time frame:
Day 1 to Week 14
Reported as:
Count of participants · Participants
Treatment Phase: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) or Adverse Event of Special Interest (AESI)
ParticipantsTreatment Phase: Bivamelagon 200 mgTreatment Phase: Bivamelagon 400 mgTreatment Phase: Bivamelagon 600 mgTreatment Phase: Placebo
Any TEAE6786
Any AESI2301
SecondaryOpen-label Extension Phase: Number of Participants Who Experienced a TEAE or AESI

A TEAE was any undesirable and unintended medical event occurring to a participant in a clinical study and which does not necessarily have a causal relationship with the study drug, with onset or worsening after the start of study drug. AESIs were events of scientific and medical interest specific to the further understanding of the safety profile of the study drug. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

Time frame:
Week 14 to Week 56
Reported as:
Count of participants · Participants
Open-label Extension Phase: Number of Participants Who Experienced a TEAE or AESI
ParticipantsOpen-label Extension Phase: Bivamelagon 200 mg to 600 mgOpen-label Extension Phase: Bivamelagon 400 mg to 600 mgOpen-label Extension Phase: Bivamelagon 600 mg to 600 mgOpen-label Extension Phase: Placebo to Bivamelagon 600 mg
Any TEAE6577
Any AESI3104
SecondaryTreatment Phase: Number of Participants Who Experienced a Mild, Moderate, Severe, Life-threatening or Fatal TEAE

TEAEs were evaluated by the investigator according to the definitions below using the following guidelines: * Mild - Asymptomatic or mild symptoms; clinical or diagnostic observations only; no intervention indicated; no disruption to daily activity. * Moderate - Discomfort sufficient to reduce or affect normal daily activity. * Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; inability to work or perform normal daily activity. * Life-threatening consequences; urgent intervention indicated. * Fatal outcome. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

Time frame:
Day 1 to Week 14
Reported as:
Count of participants · Participants
Treatment Phase: Number of Participants Who Experienced a Mild, Moderate, Severe, Life-threatening or Fatal TEAE
ParticipantsTreatment Phase: Bivamelagon 200 mgTreatment Phase: Bivamelagon 400 mgTreatment Phase: Bivamelagon 600 mgTreatment Phase: Placebo
Any Mild TEAE5244
Any Moderate TEAE1340
Any Severe TEAE0202
Any Life-threatening TEAE0000
Any Fatal TEAE0000
SecondaryOpen-label Extension Phase: Number of Participants Who Experienced a Mild, Moderate, Severe, Life-threatening or Fatal TEAE

TEAEs were evaluated by the investigator according to the definitions below using the following guidelines: * Mild - Asymptomatic or mild symptoms; clinical or diagnostic observations only; no intervention indicated; no disruption to daily activity. * Moderate - Discomfort sufficient to reduce or affect normal daily activity. * Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; inability to work or perform normal daily activity. * Life-threatening consequences; urgent intervention indicated. * Fatal outcome. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

Time frame:
Week 14 to Week 56
Reported as:
Count of participants · Participants
Open-label Extension Phase: Number of Participants Who Experienced a Mild, Moderate, Severe, Life-threatening or Fatal TEAE
ParticipantsOpen-label Extension Phase: Bivamelagon 200 mg to 600 mgOpen-label Extension Phase: Bivamelagon 400 mg to 600 mgOpen-label Extension Phase: Bivamelagon 600 mg to 600 mgOpen-label Extension Phase: Placebo to Bivamelagon 600 mg
Any Mild TEAE0323
Any Moderate TEAE4134
Any Severe TEAE2020
Any Life-threatening TEAE0100
Any Fatal TEAE0000
SecondaryTreatment Phase: Maximum Observed Concentration of Bivamelagon in Plasma (Cmax)

Pharmacokinetic (PK) parameters were derived using noncompartmental methods. Cmax was obtained directly from the observed concentration versus time data. At Week 0, all participants received bivamelagon 200 mg QD. At Week 10, participants received their maximum assigned bivamelagon dose QD.

Time frame:
Week 0 and Week 10: Pre-dose and 1, 2, 4, 6, and 24 hours post-dose
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Treatment Phase: Maximum Observed Concentration of Bivamelagon in Plasma (Cmax)
nanograms per milliliter (ng/mL)Treatment Phase: Bivamelagon 200 mgTreatment Phase: Bivamelagon 400 mgTreatment Phase: Bivamelagon 600 mg
Week 04609.8 ± 75.23624.9 ± 78.93895.2 ± 86.4
Week 105764 ± 61.410047.9 ± 48.2NA ± NA
SecondaryTreatment Phase: Time to Cmax (Tmax)

PK parameters were derived using noncompartmental methods. At Week 0, all participants received bivamelagon 200 mg QD. At Week 10, participants received their maximum assigned bivamelagon dose QD.

Time frame:
Week 0 and Week 10: Pre-dose and 1, 2, 4, 6, and 24 hours post-dose
Reported as:
Median · hours
Treatment Phase: Time to Cmax (Tmax)
hoursTreatment Phase: Bivamelagon 200 mgTreatment Phase: Bivamelagon 400 mgTreatment Phase: Bivamelagon 600 mg
Week 03.11 (1.00 to 4.03)1.88 (0.83 to 2.02)1.98 (1.00 to 4.00)
Week 101.17 (1.00 to 2.00)2.43 (0.85 to 4.00)NA (NA to NA)
SecondaryTreatment Phase: Area Under the Concentration-time Curve From 0 to Last Quantifiable Concentration (AUC0-t)

PK parameters were derived using noncompartmental methods.AUC0-t was calculated by the linear up/log down trapezoidal summation. At Week 0, all participants received bivamelagon 200 mg QD. At Week 10, participants received their maximum assigned bivamelagon dose QD.

Time frame:
Week 0 and Week 10: Pre-dose and 1, 2, 4, 6, and 24 hours post-dose
Reported as:
Geometric mean · nanogram-hours per milliliter (h*ng/mL)
Treatment Phase: Area Under the Concentration-time Curve From 0 to Last Quantifiable Concentration (AUC0-t)
nanogram-hours per milliliter (h*ng/mL)Treatment Phase: Bivamelagon 200 mgTreatment Phase: Bivamelagon 400 mgTreatment Phase: Bivamelagon 600 mg
Week 029540 ± 69.227870 ± 96.131780 ± 59.6
Week 1038250 ± 58.8102400 ± 91.6NA ± NA
SecondaryTreatment Phase: Trough Plasma Concentration (Ctrough)

PK parameters were derived using noncompartmental methods. At Week 0, all participants received bivamelagon 200 mg QD. At Week 10, participants received their maximum assigned bivamelagon dose QD.

Time frame:
Weeks 1, 2, 6, 10, and 14: Pre-dose
Reported as:
Geometric mean · ng/mL
Treatment Phase: Trough Plasma Concentration (Ctrough)
ng/mLTreatment Phase: Bivamelagon 200 mgTreatment Phase: Bivamelagon 400 mgTreatment Phase: Bivamelagon 600 mg
Week 1297.8 ± 44.6545.5 ± 118.9NA ± NA
Week 2339.6 ± 42.01024.6 ± 172.2NA ± NA
Week 6365.7 ± 39.61136.5 ± 126.1NA ± NA
Week 10441.8 ± 51.52166.7 ± 212.7NA ± NA
Week 14343.1 ± 60.71001 ± 210.1NA ± NA

Adverse events

Collected over Treatment Phase: Day 1 to Week 14. Open-label Extension Phase: Week 14 to Week 56. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment Phase: Bivamelagon 200 mg0/6 (0%)0/6 (0%)6/6 (100%)
Treatment Phase: Bivamelagon 400 mg0/7 (0%)1/7 (14.3%)7/7 (100%)
Treatment Phase: Bivamelagon 600 mg0/8 (0%)0/8 (0%)8/8 (100%)
Treatment Phase: Placebo0/7 (0%)1/7 (14.3%)6/7 (85.7%)
Open-label Extension Phase: Bivamelagon 200 mg to 600 mg0/6 (0%)2/6 (33.3%)6/6 (100%)
Open-label Extension Phase: Bivamelagon 400 mg to 600 mg0/6 (0%)1/6 (16.7%)5/6 (83.3%)
Open-label Extension Phase: Bivamelagon 600 mg to 600 mg0/7 (0%)1/7 (14.3%)7/7 (100%)
Open-label Extension Phase: Placebo to Bivamelagon 600 mg0/7 (0%)0/7 (0%)7/7 (100%)
Most frequent serious events
Most frequent serious events
EventTreatment Phase: Bivamelagon 200 mgTreatment Phase: Bivamelagon 400 mgTreatment Phase: Bivamelagon 600 mgTreatment Phase: PlaceboOpen-label Extension Phase: Bivamelagon 200 mg to 600 mgOpen-label Extension Phase: Bivamelagon 400 mg to 600 mgOpen-label Extension Phase: Bivamelagon 600 mg to 600 mgOpen-label Extension Phase: Placebo to Bivamelagon 600 mg
Anaphylactic reactionImmune system disorders0/60/70/80/70/61/60/70/7
HyponatraemiaMetabolism and nutrition disorders0/60/70/80/71/60/60/70/7
Tonsillar hypertrophyRespiratory, thoracic and mediastinal disorders0/60/70/80/71/60/60/70/7
HaematocheziaGastrointestinal disorders0/61/70/80/70/60/60/70/7
Chest painGeneral disorders0/60/70/81/70/60/60/70/7
GastroenteritisInfections and infestations0/60/70/80/70/60/61/70/7
Most frequent other events
Showing 10 of 112
Most frequent other events
EventTreatment Phase: Bivamelagon 200 mgTreatment Phase: Bivamelagon 400 mgTreatment Phase: Bivamelagon 600 mgTreatment Phase: PlaceboOpen-label Extension Phase: Bivamelagon 200 mg to 600 mgOpen-label Extension Phase: Bivamelagon 400 mg to 600 mgOpen-label Extension Phase: Bivamelagon 600 mg to 600 mgOpen-label Extension Phase: Placebo to Bivamelagon 600 mg
NauseaGastrointestinal disorders6/65/74/82/74/63/61/74/7
DiarrhoeaGastrointestinal disorders2/65/73/81/73/62/61/73/7
VomitingGastrointestinal disorders2/64/74/82/74/64/61/75/7
HeadacheNervous system disorders1/65/71/82/71/62/61/73/7
Abdominal painGastrointestinal disorders1/62/71/80/70/61/61/73/7
EpistaxisRespiratory, thoracic and mediastinal disorders2/60/70/80/70/60/60/70/7
Viral upper respiratory tract infectionInfections and infestations2/60/70/81/70/60/60/70/7
NasopharyngitisInfections and infestations1/62/70/81/71/62/61/70/7
FatigueGeneral disorders1/62/71/80/70/62/60/71/7
Skin hyperpigmentationSkin and subcutaneous tissue disorders0/61/70/81/72/60/60/72/7

Baseline characteristics

The Modified Intent-to-Treat (mITT) set included all randomized participants in the Treatment Phase who were exposed to at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Treatment Phase: Bivamelagon 200 mgTreatment Phase: Bivamelagon 400 mgTreatment Phase: Bivamelagon 600 mgTreatment Phase: PlaceboTotal
Mean20.2 ± 9.1521.0 ± 7.9431.9 ± 23.0227.0 ± 20.1725.4 ± 16.78
Sex: Female, Male
Sex: Female, Male(Participants)Treatment Phase: Bivamelagon 200 mgTreatment Phase: Bivamelagon 400 mgTreatment Phase: Bivamelagon 600 mgTreatment Phase: PlaceboTotal
Female343313
Male335415
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment Phase: Bivamelagon 200 mgTreatment Phase: Bivamelagon 400 mgTreatment Phase: Bivamelagon 600 mgTreatment Phase: PlaceboTotal
Hispanic or Latino00224
Not Hispanic or Latino676524
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment Phase: Bivamelagon 200 mgTreatment Phase: Bivamelagon 400 mgTreatment Phase: Bivamelagon 600 mgTreatment Phase: PlaceboTotal
American Indian or Alaska Native00000
Asian02103
Native Hawaiian or Other Pacific Islander00000
Black or African American00112
White555621
More than one race10001
Unknown or Not Reported00101
08

Study locations

10 sites
  • Children's Hospital Colorado
    Aurora, Colorado 80045, United States
  • University of Iowa Children's Hospital
    Iowa City, Iowa 52242, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • Columbia University
    New York, New York 10027, United States
  • The University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27514, United States
  • Lynn Health Science Institute
    Oklahoma City, Oklahoma 73112, United States
  • St. Jude Children's Research Hospital
    Memphis, Tennessee 38105, United States
  • Birmingham Women's and Children's NHS Foundation Trust
    Birmingham, B15 2TG, United Kingdom
  • University of Cambridge
    Cambridge, CB2 1TN, United Kingdom
  • Great Ormond Street Hospital for Children
    London, WC1N 3JH, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2024 to primary completion in Feb 2026, 18 months.

Results were first posted in Oct 2026, 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2023
First posted
Sep 21, 2023
StartActual
Jul 11, 2024
Primary completionActual
Feb 9, 2026
CompletionActual
Feb 9, 2026
Results first posted
Oct 30, 2026
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 30, 2026
Eligibility
4 criteria edited
What changed in the criteria
  • EditedWeight gain associated with the hypothalamic injury and a body mass index (BMI) of ≥30 kg/m2m\^2 for patientsparticipants ≥18 years of age or BMI ≥95th percentile for age and sex for patientsparticipants <18 years of age
  • EditedMale and female participants agreeagreed to follow study contraception requirements and use a highly effective form of contraception throughout the study and for 90 days after the study
  • EditedWeight loss >2% in the previous 3 months for patientsparticipants ≥18 years of age or >2% reduction in BMI for patientsparticipants <18 years of age
  • EditedCurrent clinicallyClinically significant pulmonary, cardiac, or oncologic disease considered severe enough to interfere with the study and/or confound the results
Oct 30, 2026
Interventions
Changed LB54640→Bivamelagon. Arm changed Open-label LB54640→Open-label Bivamelagon. Arms added: Bivamelagon Low dose (200 milligrams [mg])·Bivamelagon Middle dose (400 mg)·Bivamelagon High dose (600 mg); arms removed: LB54640 Low dose·LB54640 Middle dose·LB54640 High dose
Oct 30, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Mean percentage change in BMINow Treatment Phase: Mean Percentage Change From Baseline to Week 14 in Body Mass Index (BMI)Time frame: From Baseline to Week 14 → Baseline, Week 14
Oct 30, 2026
Documents
Secondary outcomes
6 edited, 24 added, 5 more
What changed in the outcomes
  • EditedTreatment Phase: Mean changeChange From Baseline in BMITime frame: Baseline to Weeks 6, 10, 14 → Baseline, Week 6, Week 10, and Week 14
  • EditedProportionTreatment Phase: Percentage of patients who achieveParticipants Who Achieved at Least a ≥5% reductionor ≥10% Reduction in body weightBody WeightTime frame: Baseline to Week 14
  • EditedTreatment Phase: Mean changeChange From Baseline in the weekly averageWeekly Average of the daily most hunger scoreDaily Most Hunger ScoreTime frame: Baseline to Week 14 → Baseline, Week 14
  • EditedTreatment Phase: Mean change and mean percentage change from baselineChange From Baseline in body weightBody WeightTime frame: From Baseline to Week 52 → Baseline, Week 6, Week 10, and Week 14
  • EditedTreatment Phase: Mean change and mean percentage change from baselinePercentage Change From Baseline in waist circumference.Body WeightTime frame: From Baseline to Week 52 → Baseline, Week 6, Week 10, and Week 14
  • EditedTreatment Phase: Mean change and mean percentage change from baselineChange From Baseline in body composition assessed by dual energy x-ray absorptiometryBody CompositionTime frame: From Baseline to Week 52 → Baseline, Week 14
  • AddedTreatment Phase: Mean Percentage Change From Baseline to Weeks 6 and 10 in BMITime frame: Baseline, Week 6 and Week 10
  • AddedTreatment Phase (Participants < 18 Years): Mean Change From Baseline in the Gender- and Age-specific BMI Z-ScoreTime frame: Baseline, Week 6, Week 10, and Week 14
  • AddedTreatment Phase (Participants < 18 Years): Mean Change From Baseline in the Percentage of the Gender- and Age-specific 95th Percentile of BMITime frame: Baseline, Week 6, Week 10, and Week 14
  • AddedTreatment Phase: Percentage of Participants Who Achieved at Least a ≥5% or ≥10% Reduction in BMITime frame: Baseline to Week 14
  • AddedTreatment Phase: Mean Change From Baseline in Waist CircumferenceTime frame: Baseline, Week 6, Week 10, and Week 14
  • AddedTreatment Phase: Mean Percentage Change From Baseline in Waist CircumferenceTime frame: Baseline, Week 6, Week 10, and Week 14
  • AddedTreatment Phase: Mean Change From Baseline in Waist-to-hip Circumference RatioTime frame: Baseline, Week 6, Week 10, and Week 14
  • AddedTreatment Phase: Mean Percentage Change From Baseline in Waist-to-hip Circumference RatioTime frame: Baseline, Week 6, Week 10, and Week 14
  • AddedTreatment Phase: Mean Percentage Change From Baseline in Body CompositionTime frame: Baseline, Week 14
  • AddedTreatment Phase: Mean Change From Baseline in the Weekly Average of the Symptoms of Hyperphagia Composite ScoreTime frame: Baseline, Week 14
  • AddedOpen-label Extension Phase: Mean Change From Baseline in BMITime frame: Baseline, Week 28 and Week 52
  • AddedOpen-label Extension Phase: Mean Percentage Change From Baseline in BMITime frame: Baseline, Week 28 and Week 52
  • AddedOpen-label Extension Phase: Mean Change From Baseline in Body WeightTime frame: Baseline, Week 28 and Week 52
  • AddedOpen-label Extension Phase: Mean Percentage Change From Baseline in Body WeightTime frame: Baseline, Week 28 and Week 52
  • AddedOpen-label Extension Phase: Mean Change From Baseline in Waist CircumferenceTime frame: Baseline, Week 28 and Week 52
  • AddedOpen-label Extension Phase: Mean Percentage Change From Baseline in Waist CircumferenceTime frame: Baseline, Week 28 and Week 52
  • AddedOpen-label Extension Phase: Mean Change From Baseline in Waist-to-hip Circumference RatioTime frame: Baseline, Week 28 and Week 52
  • AddedOpen-label Extension Phase: Mean Percentage Change From Baseline in Waist-to-hip Circumference RatioTime frame: Baseline, Week 28 and Week 52
  • AddedOpen-label Extension Phase: Mean Change From Baseline in Body CompositionTime frame: Baseline, Week 52
  • AddedOpen-label Extension Phase: Mean Percentage Change From Baseline in Body CompositionTime frame: Baseline, Week 52
  • AddedTreatment Phase: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) or Adverse Event of Special Interest (AESI)Time frame: Day 1 to Week 14
  • AddedOpen-label Extension Phase: Number of Participants Who Experienced a TEAE or AESITime frame: Week 14 to Week 56
  • AddedTreatment Phase: Number of Participants Who Experienced a Mild, Moderate, Severe, Life-threatening or Fatal TEAETime frame: Day 1 to Week 14
  • AddedOpen-label Extension Phase: Number of Participants Who Experienced a Mild, Moderate, Severe, Life-threatening or Fatal TEAETime frame: Week 14 to Week 56
  • …and 5 more, on the record history on ClinicalTrials.gov ↗
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Results posted
    Eligibility 4 criteria edited
    What changed in the criteria
    • EditedWeight gain associated with the hypothalamic injury and a body mass index (BMI) of ≥30 kg/m2m\^2 for patientsparticipants ≥18 years of age or BMI ≥95th percentile for age and sex for patientsparticipants <18 years of age
    • EditedMale and female participants agreeagreed to follow study contraception requirements and use a highly effective form of contraception throughout the study and for 90 days after the study
    • EditedWeight loss >2% in the previous 3 months for patientsparticipants ≥18 years of age or >2% reduction in BMI for patientsparticipants <18 years of age
    • EditedCurrent clinicallyClinically significant pulmonary, cardiac, or oncologic disease considered severe enough to interfere with the study and/or confound the results
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Mean percentage change in BMINow Treatment Phase: Mean Percentage Change From Baseline to Week 14 in Body Mass Index (BMI)Time frame: From Baseline to Week 14 → Baseline, Week 14
    Secondary outcomes 6 edited, 24 added, 5 more
    What changed in the outcomes
    • EditedTreatment Phase: Mean changeChange From Baseline in BMITime frame: Baseline to Weeks 6, 10, 14 → Baseline, Week 6, Week 10, and Week 14
    • EditedProportionTreatment Phase: Percentage of patients who achieveParticipants Who Achieved at Least a ≥5% reductionor ≥10% Reduction in body weightBody WeightTime frame: Baseline to Week 14
    • EditedTreatment Phase: Mean changeChange From Baseline in the weekly averageWeekly Average of the daily most hunger scoreDaily Most Hunger ScoreTime frame: Baseline to Week 14 → Baseline, Week 14
    • EditedTreatment Phase: Mean change and mean percentage change from baselineChange From Baseline in body weightBody WeightTime frame: From Baseline to Week 52 → Baseline, Week 6, Week 10, and Week 14
    • EditedTreatment Phase: Mean change and mean percentage change from baselinePercentage Change From Baseline in waist circumference.Body WeightTime frame: From Baseline to Week 52 → Baseline, Week 6, Week 10, and Week 14
    • EditedTreatment Phase: Mean change and mean percentage change from baselineChange From Baseline in body composition assessed by dual energy x-ray absorptiometryBody CompositionTime frame: From Baseline to Week 52 → Baseline, Week 14
    • AddedTreatment Phase: Mean Percentage Change From Baseline to Weeks 6 and 10 in BMITime frame: Baseline, Week 6 and Week 10
    • AddedTreatment Phase (Participants < 18 Years): Mean Change From Baseline in the Gender- and Age-specific BMI Z-ScoreTime frame: Baseline, Week 6, Week 10, and Week 14
    • AddedTreatment Phase (Participants < 18 Years): Mean Change From Baseline in the Percentage of the Gender- and Age-specific 95th Percentile of BMITime frame: Baseline, Week 6, Week 10, and Week 14
    • AddedTreatment Phase: Percentage of Participants Who Achieved at Least a ≥5% or ≥10% Reduction in BMITime frame: Baseline to Week 14
    • AddedTreatment Phase: Mean Change From Baseline in Waist CircumferenceTime frame: Baseline, Week 6, Week 10, and Week 14
    • AddedTreatment Phase: Mean Percentage Change From Baseline in Waist CircumferenceTime frame: Baseline, Week 6, Week 10, and Week 14
    • AddedTreatment Phase: Mean Change From Baseline in Waist-to-hip Circumference RatioTime frame: Baseline, Week 6, Week 10, and Week 14
    • AddedTreatment Phase: Mean Percentage Change From Baseline in Waist-to-hip Circumference RatioTime frame: Baseline, Week 6, Week 10, and Week 14
    • AddedTreatment Phase: Mean Percentage Change From Baseline in Body CompositionTime frame: Baseline, Week 14
    • AddedTreatment Phase: Mean Change From Baseline in the Weekly Average of the Symptoms of Hyperphagia Composite ScoreTime frame: Baseline, Week 14
    • AddedOpen-label Extension Phase: Mean Change From Baseline in BMITime frame: Baseline, Week 28 and Week 52
    • AddedOpen-label Extension Phase: Mean Percentage Change From Baseline in BMITime frame: Baseline, Week 28 and Week 52
    • AddedOpen-label Extension Phase: Mean Change From Baseline in Body WeightTime frame: Baseline, Week 28 and Week 52
    • AddedOpen-label Extension Phase: Mean Percentage Change From Baseline in Body WeightTime frame: Baseline, Week 28 and Week 52
    • AddedOpen-label Extension Phase: Mean Change From Baseline in Waist CircumferenceTime frame: Baseline, Week 28 and Week 52
    • AddedOpen-label Extension Phase: Mean Percentage Change From Baseline in Waist CircumferenceTime frame: Baseline, Week 28 and Week 52
    • AddedOpen-label Extension Phase: Mean Change From Baseline in Waist-to-hip Circumference RatioTime frame: Baseline, Week 28 and Week 52
    • AddedOpen-label Extension Phase: Mean Percentage Change From Baseline in Waist-to-hip Circumference RatioTime frame: Baseline, Week 28 and Week 52
    • AddedOpen-label Extension Phase: Mean Change From Baseline in Body CompositionTime frame: Baseline, Week 52
    • AddedOpen-label Extension Phase: Mean Percentage Change From Baseline in Body CompositionTime frame: Baseline, Week 52
    • AddedTreatment Phase: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) or Adverse Event of Special Interest (AESI)Time frame: Day 1 to Week 14
    • AddedOpen-label Extension Phase: Number of Participants Who Experienced a TEAE or AESITime frame: Week 14 to Week 56
    • AddedTreatment Phase: Number of Participants Who Experienced a Mild, Moderate, Severe, Life-threatening or Fatal TEAETime frame: Day 1 to Week 14
    • AddedOpen-label Extension Phase: Number of Participants Who Experienced a Mild, Moderate, Severe, Life-threatening or Fatal TEAETime frame: Week 14 to Week 56
    • …and 5 more, on the record history on ClinicalTrials.gov ↗
    Interventions Changed LB54640→Bivamelagon. Arm changed Open-label LB54640→Open-label Bivamelagon. Arms added: Bivamelagon Low dose (200 milligrams [mg])·Bivamelagon Middle dose (400 mg)·Bivamelagon High dose (600 mg); arms removed: LB54640 Low dose·LB54640 Middle dose·LB54640 High dose
    + 3 other changes: verification date, description and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06046443
Responsible party
Sponsor
First posted
Sep 21, 2023
Start date
Jul 11, 2024
Primary completion
Feb 9, 2026
Completion
Feb 9, 2026
Results posted
Oct 30, 2026
Last update
Oct 30, 2026

Study contacts

David Meeker, MD
study chair · Rhythm Pharmaceuticals, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bivamelagon

Start the discussion